4 recruiting, 1 completed, 1 enrolling by invitation. 5 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Completed 1, Enrolling by invitation 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Induction Phase: new trials by email Literature Review of Induction Phase trials Research Report on Induction Phase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia Induction Phase, Re-Induction Phase, Post-Remission - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, CD19+ Acute Leukemia | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 55 | 2026-04-13 | 2026-10-05 |
| Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease Orelabrutinib, Rituximab (R), Lisaftoclax (APG-2575) - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Ruijin Hospital | 25 | 2025-09-10 | 2026-07-28 |
| A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapy - Mantle-cell Lymphoma | Phase 2 | Recruiting | AstraZeneca | 55 | 2025-09-05 | 2026-10-02 |
| Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma Pomalidomide, Orelabrutinib, Zuberitamab - Mantle Cell Lymphoma (MCL), POZ | Not applicable | Recruiting | Peking University Third Hospital | 34 | 2025-08-01 | 2025-12-02 |
| Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment Orelabrutinib, Rituximab (R), BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan) - Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Ruijin Hospital | 45 | 2025-07-01 | 2025-09-30 |
| Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma Induction Phase, Consolidation Phase (on day +50), Intensification phase - HIV, Burkitt's Lymphoma | Phase 2 | Completed | Andres J. M. Ferreri | 19 | 2011-11-01 | 2022-08-04 |
Lymphoma, Mantle-Cell (4) · Burkitt Lymphoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Ruijin Hospital (2) · Andres J. M. Ferreri (1) · AstraZeneca (1) · Peking University Third Hospital (1) · SWOG Cancer Research Network (1)
China (3) · Italy (1) · Spain (1) · United States (1)
Anjali S Advani (1)